The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
There is no competition. LTH are here for tils......nothing else! If you've done your research you'll appreciate the companies largely operate in different areas of development, have different capitalisations, &, therefore, are not comparable.
Keep the board focus on Tiziana.
Or you could take the view that there's a lot of waffal/le being spouted on here by investors who haven't a clue what's going on, other than a further promising collaboration.
"A total of 18 of Astrea’s adsorbents have been incorporated into FDA approved manufacturing processes which produce 12 approved pharmaceutical and medical products"
Gkb "8 December 2020 - e-therapeutics plc (AIM: ETX) announces the results of experimental testing on the compounds for the treatment of COVID-19 identified using its proprietary Network-driven Drug Discovery (NDD) platform" etc, an rns to which you reacted very positively. Note, not a criticism, just observation, it sounds interesting & hope your investment is successful.
Your earlier posting "...miss the damn race" suggests the covid pandemic will be all over before we get to market. Aren't etx in a similar position, & will "miss the damn race"?
Gkb. Point is, whatever they're developing, they are no where near getting it to market as a covid offering. "It's no good having the fatest racing car if you miss the damn race."
So, to repeat my question, why the difference in sentiment.
Could be associated with this https://uk.reuters.com/article/us-health-coronavirus-daewoong-pharm/south-korea-daewoong-pharma-eyes-phase-ii-trials-of-coronavirus-drug-shares-jump-idUKKBN28D0IX
SC, seem to be different. "In the past decades, multiple alternatives to antibodies have been developed, including affibodies [21], aptamers [22], single-chain variable fragments [23] and Affimer® reagents (from here on referred to as affimer) [24]. Of these, affimers are small and stable recombinant proteins that are based on a stable protein scaffold, derived from the cysteine protease inhibitor family of cystatins, which function in nature as cysteine protease inhibitors."
Link. https://www.sciencedirect.com/science/article/pii/S1046592820301182
Mnss. If you can, restrict you're viewing of this board to a minimum. If you want to follow official news only, suggest you try Investegate, Directors Talk, Vox Markets, & Avacta's news releases. As you know there are a few excellent contributors on this board, but as I said yesterday, most posts are at the very best, speculation, & at worst, defammatory.
If you have researched avct, & follow official communiqués, it would be difficult to find someone on this board actually better informed than you. As you say "Timely reminders of what underpins our belief in the Avacta investment case are really useful", but these must come from official sources, certainly not from any BB.
All genuine holders should avoid second guessing 'where we are'. It provides fodder for all those whose only intention is to disrupt. For reasons beyond me some will offer a review/background to avct, but those who've done just a little research can see the wide rangeing possibilities. And they are only possibilities until 'the eagle has landed'.
A lot less speculation would do us all a favour. If one no longer has faith in the Company, the Board, the CEO, or the offering, the best thing to do is sell, no point in continually bemoaning the lack of news, or the misleading RNS, etc. By selling you will no longer have the anxiety that (for some) accompanies this investment.
Nr11, "discussion on this board has all but trashed the idea of a successful saliva antigen test", that's the problem, 'dicussion' has become 'fact'. Expectation/anticipation has also become 'fact'. A timeline of events is suggested on this BB, in very short order it gets twisted into 'fact', & a little later into 'what we've been promised', which is then regurgitated as nauseum.
JH, thanks for response. Hope you're correct.
Conspiracy conjecture only. Could it be GC happy to see the share slide, at some stage to take Tiziana private? Appreciate probable rubbish, but offers a (controversial) rationale for the current situation.
SCat, could also be cost to HMG. Seems swab will be cheaper than saliva - I think £6 has previously been mooted. If successful, the saliva test will probably be taken up by airports/airlines etc, & will command a much better selling price.
Infinity I have also wondered about the test/bbi, as BAMS is Adeptrix. I believe cytiva only developed the original 'vehicle' on our behalf, however, it seems quite possible the body for the nasal swab belongs to bbi. If so, would avct be involved with identifying additional manufacturing capacity?
Moniman extract from the £45m fund raise rns,. Where are the undelivered promises?
Pursuant to the Fundraising, the Company proposes to raise up to £45 million (before expenses) to fund the rapid scale-up of the broader Affimer® diagnostic products opportunities including COVID-19 antigen rapid testing and accelerated expansion of the in-house Affimer® and pre|CISION™ cancer therapy pipeline
Girlupnorth, from yesterday rns
The development of an Affimer-based lateral flow antigen test that can be manufactured at scale being carried out in partnership with BBI Solutions has made substantial progress. A highly scalable test device using readily available components and routine manufacturing processes has now been shown to have a sensitivity for coronavirus spike protein in laboratory samples better than 300 pg/ml which is in the range expected for spike protein in clinical samples.